Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer

Overview

Journal Diabetes

Specialty Endocrinology

Date 2017 May 17

PMID 28507210

Citations 182

Authors

Dana K Andersen

Murray Korc

Gloria M Petersen

Guido Eibl

Donghui Li

Michael R Rickels

Suresh T Chari

James L Abbruzzese

Affiliations

Soon will be listed here.

Abstract

The relationships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex. Longstanding type 2 diabetes (T2DM) is a risk factor for pancreatic cancer, but increasing epidemiological data point to PDAC as also a cause of diabetes due to unknown mechanisms. New-onset diabetes is of particular interest to the oncology community as the differentiation of new-onset diabetes caused by PDAC as distinct from T2DM may allow for earlier diagnosis of PDAC. To address these relationships and raise awareness of the relationships between PDAC and diabetes, a symposium entitled Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer was held at the American Diabetes Association's 76th Scientific Sessions in June 2016. This article summarizes the data presented at that symposium, describing the current understanding of the interrelationships between diabetes, diabetes management, and pancreatic cancer, and identifies areas where additional research is needed.

Citing Articles

Insulin resistance and cancer: molecular links and clinical perspectives.

Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L Mol Cell Biochem. 2025; .

PMID: 40089612 DOI: 10.1007/s11010-025-05245-8.

Global disease burden of breast cancer attributable to high fasting plasma glucose: a comprehensive analysis from the global burden of disease study.

Zhang J, He J, Lu Y, Lan T Front Endocrinol (Lausanne). 2025; 16:1498207.

PMID: 40017691 PMC: 11864957. DOI: 10.3389/fendo.2025.1498207.

A comparison of the burden of cancers between 1990 and 2019 in Iran: A national and subnational study.

Darbandi M, Khorrami Z, Karamoozian A, Aboubakri O, Miryan M, Rezakhani L PLoS One. 2025; 20(2):e0309699.

PMID: 39999060 PMC: 11856284. DOI: 10.1371/journal.pone.0309699.

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.

Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals.

Heller M, Mann D, Katona B J Gastrointest Cancer. 2025; 56(1):61.

PMID: 39932614 PMC: 11814005. DOI: 10.1007/s12029-025-01184-1.

References

Whitcomb D, LaRusch J, Krasinskas A, Klei L, Smith J, Brand R . Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet. 2012; 44(12):1349-54. PMC: 3510344. DOI: 10.1038/ng.2466. View

Everhart J, Wright D . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273(20):1605-9. View

Aggarwal G, Kamada P, Chari S . Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2012; 42(2):198-201. PMC: 3896296. DOI: 10.1097/MPA.0b013e3182592c96. View

Hu C, Hart S, Bamlet W, Moore R, Nandakumar K, Eckloff B . Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):207-11. PMC: 4754121. DOI: 10.1158/1055-9965.EPI-15-0455. View

Kahn S . The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46(1):3-19. DOI: 10.1007/s00125-002-1009-0. View

Hardt P, Brendel M, Kloer H, Bretzel R . Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed?. Diabetes Care. 2008; 31 Suppl 2:S165-9. DOI: 10.2337/dc08-s244. View

Colmers I, Bowker S, Tjosvold L, Johnson J . Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012; 38(6):485-506. DOI: 10.1016/j.diabet.2012.08.011. View

Wang Z, Lai S, Xie L, Zhao J, Ma N, Zhu J . Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014; 106(1):19-26. DOI: 10.1016/j.diabres.2014.04.007. View

Ewald N, Bretzel R . Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?. Eur J Intern Med. 2013; 24(3):203-6. DOI: 10.1016/j.ejim.2012.12.017. View

10.

Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G . Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause?. Clin Chim Acta. 2006; 372(1-2):120-8. DOI: 10.1016/j.cca.2006.03.027. View

11.

Pelaez-Luna M, Takahashi N, Fletcher J, Chari S . Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007; 102(10):2157-63. DOI: 10.1111/j.1572-0241.2007.01480.x. View

12.

Domschke S, Stock K, Pichl J, Schneider M, Domschke W . Beta-cell reserve capacity in chronic pancreatitis. Hepatogastroenterology. 1985; 32(1):27-30. View

13.

Madiraju A, Erion D, Rahimi Y, Zhang X, Braddock D, Albright R . Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510(7506):542-6. PMC: 4074244. DOI: 10.1038/nature13270. View

14.

Leclerc E, Vetter S . The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta. 2015; 1852(12):2706-11. PMC: 4643662. DOI: 10.1016/j.bbadis.2015.09.022. View

15.

He X, Yuan Y . Advances in pancreatic cancer research: moving towards early detection. World J Gastroenterol. 2014; 20(32):11241-8. PMC: 4145762. DOI: 10.3748/wjg.v20.i32.11241. View

16.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

17.

Vongsuvanh R, George J, Qiao L, van der Poorten D . Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 2012; 330(1):1-10. DOI: 10.1016/j.canlet.2012.11.038. View

18.

Philip B, Roland C, Daniluk J, Liu Y, Chatterjee D, Gomez S . A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013; 145(6):1449-58. PMC: 3873752. DOI: 10.1053/j.gastro.2013.08.018. View

19.

Roberts N, Jiao Y, Yu J, Kopelovich L, Petersen G, Bondy M . ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2(1):41-6. PMC: 3676748. DOI: 10.1158/2159-8290.CD-11-0194. View

20.

Menke A, Casagrande S, Geiss L, Cowie C . Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015; 314(10):1021-9. DOI: 10.1001/jama.2015.10029. View